 Shannon Kasperbauer
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 18 | 2025 | 360 | 4.800 |
Why?
| | Nontuberculous Mycobacteria | 14 | 2025 | 205 | 3.220 |
Why?
| | Bronchiectasis | 3 | 2025 | 111 | 2.010 |
Why?
| | Lung Diseases | 8 | 2024 | 768 | 1.450 |
Why?
| | Cystic Fibrosis | 4 | 2025 | 1108 | 1.080 |
Why?
| | Immunocompromised Host | 2 | 2018 | 202 | 0.880 |
Why?
| | Anti-Bacterial Agents | 9 | 2025 | 1797 | 0.780 |
Why?
| | Equipment Contamination | 1 | 2019 | 64 | 0.600 |
Why?
| | Mycobacterium Infections | 1 | 2019 | 63 | 0.590 |
Why?
| | Mycobacterium | 1 | 2019 | 108 | 0.550 |
Why?
| | Drug Resistance, Bacterial | 3 | 2019 | 185 | 0.550 |
Why?
| | Mycobacterium avium Complex | 3 | 2021 | 88 | 0.550 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2018 | 67 | 0.550 |
Why?
| | Disease Outbreaks | 1 | 2019 | 386 | 0.480 |
Why?
| | Heart Diseases | 1 | 2019 | 346 | 0.480 |
Why?
| | Disease Management | 1 | 2019 | 624 | 0.450 |
Why?
| | Mycobacterium abscessus | 2 | 2025 | 114 | 0.350 |
Why?
| | Incidence | 3 | 2025 | 2792 | 0.300 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2008 | 62 | 0.280 |
Why?
| | Sex Factors | 2 | 2025 | 2060 | 0.250 |
Why?
| | Phage Therapy | 1 | 2025 | 15 | 0.240 |
Why?
| | Humans | 22 | 2025 | 136765 | 0.210 |
Why?
| | Diagnostic Tests, Routine | 3 | 2019 | 110 | 0.200 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2025 | 326 | 0.180 |
Why?
| | Peptidyl Transferases | 1 | 2020 | 8 | 0.170 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 52 | 0.170 |
Why?
| | Masks | 1 | 2020 | 63 | 0.160 |
Why?
| | Mycobacterium fortuitum | 1 | 2019 | 2 | 0.160 |
Why?
| | Clarithromycin | 1 | 2019 | 28 | 0.160 |
Why?
| | Durable Medical Equipment | 1 | 2019 | 5 | 0.160 |
Why?
| | Tertiary Care Centers | 1 | 2019 | 159 | 0.150 |
Why?
| | Musculoskeletal Diseases | 1 | 2019 | 77 | 0.140 |
Why?
| | Internationality | 1 | 2019 | 154 | 0.140 |
Why?
| | Antibiotics, Antitubercular | 1 | 2018 | 37 | 0.140 |
Why?
| | Risk Factors | 2 | 2025 | 10325 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 266 | 0.140 |
Why?
| | United States | 6 | 2020 | 14690 | 0.130 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1044 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 358 | 0.120 |
Why?
| | o-Phthalaldehyde | 1 | 2014 | 3 | 0.110 |
Why?
| | Glutaral | 1 | 2014 | 16 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1055 | 0.110 |
Why?
| | Disinfectants | 1 | 2014 | 39 | 0.110 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 184 | 0.110 |
Why?
| | Antitubercular Agents | 2 | 2019 | 203 | 0.100 |
Why?
| | Serologic Tests | 1 | 2012 | 54 | 0.100 |
Why?
| | Pandemics | 1 | 2020 | 1612 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2667 | 0.080 |
Why?
| | Female | 6 | 2025 | 72795 | 0.080 |
Why?
| | Ethambutol | 1 | 2008 | 26 | 0.070 |
Why?
| | Microbial Sensitivity Tests | 2 | 2020 | 357 | 0.070 |
Why?
| | Rifampin | 1 | 2008 | 84 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1062 | 0.060 |
Why?
| | Adult | 4 | 2025 | 37631 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 308 | 0.050 |
Why?
| | beta-Lactamase Inhibitors | 1 | 2020 | 6 | 0.040 |
Why?
| | Carboxypeptidases | 1 | 2020 | 13 | 0.040 |
Why?
| | Azabicyclo Compounds | 1 | 2020 | 6 | 0.040 |
Why?
| | Imipenem | 1 | 2020 | 18 | 0.040 |
Why?
| | Biomedical Engineering | 1 | 2020 | 27 | 0.040 |
Why?
| | Textiles | 1 | 2020 | 22 | 0.040 |
Why?
| | Cephalosporins | 1 | 2020 | 47 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 60 | 0.040 |
Why?
| | Colorado | 2 | 2020 | 4515 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2019 | 79 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 232 | 0.040 |
Why?
| | Aged | 4 | 2019 | 23794 | 0.040 |
Why?
| | Sputum | 1 | 2020 | 311 | 0.040 |
Why?
| | Prosthesis-Related Infections | 1 | 2019 | 95 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2019 | 128 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2019 | 15504 | 0.030 |
Why?
| | Middle Aged | 4 | 2019 | 33228 | 0.030 |
Why?
| | Hospitals | 1 | 2020 | 684 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1614 | 0.030 |
Why?
| | Health Personnel | 1 | 2020 | 701 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 1127 | 0.030 |
Why?
| | Prospective Studies | 1 | 2025 | 7572 | 0.020 |
Why?
| | Male | 4 | 2025 | 67311 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 898 | 0.020 |
Why?
| | Glycolipids | 1 | 2012 | 42 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.020 |
Why?
| | Antigens, Bacterial | 1 | 2012 | 129 | 0.020 |
Why?
| | Antibodies, Bacterial | 1 | 2012 | 146 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 2012 | 210 | 0.020 |
Why?
| | ROC Curve | 1 | 2012 | 545 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2025 | 10745 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1935 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7585 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4062 | 0.020 |
Why?
| | Young Adult | 1 | 2019 | 13127 | 0.010 |
Why?
|
|
Kasperbauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|